Page last updated: 2024-09-02

tadalafil and Cardiomyopathies

tadalafil has been researched along with Cardiomyopathies in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's5 (71.43)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Abuawad, Z; Andelova, K; Fulop, M; Kalocayova, B; Kura, B; Sagatova, A; Slezak, J; Sykora, M; Szeiffova Bacova, B1
Guo, H; Hong, B; Jin, Z; Li, L; Zhang, J; Zhang, S; Zhi, H1
Chau, VQ; Hoke, NN; Kukreja, RC; Salloum, FN1
Ahmed, AA; Elnakish, MT; Floyd, K; Janssen, PM; Mohler, PJ; Saad, NS1
Forbes, SC; Hammers, DW; Shima, A; Sleeper, MM; Sweeney, HL; Walter, GA1
Das, A; Durrant, D; Koka, S; Kukreja, RC; Xi, L; Zhu, SG1
Kukreja, RC1

Other Studies

7 other study(ies) available for tadalafil and Cardiomyopathies

ArticleYear
The effect of selected drugs on the mitigation of myocardial injury caused by gamma radiation.
    Canadian journal of physiology and pharmacology, 2021, Volume: 99, Issue:1

    Topics: Animals; Atorvastatin; Cardiomyopathies; Free Radicals; Gamma Rays; Heart; Male; Malondialdehyde; Myocardium; Oxidative Stress; Radiation Injuries, Experimental; Rats; Tadalafil; Treatment Outcome; Tumor Necrosis Factor-alpha

2021
Beneficial effects of tadalafil on left ventricular dysfunction in doxorubicin-induced cardiomyopathy.
    Journal of cardiology, 2013, Volume: 62, Issue:2

    Topics: Animals; Antibiotics, Antineoplastic; Atrophy; Carbolines; Cardiomyopathies; Cardiotonic Agents; Cyclic GMP; Disease Models, Animal; Doxorubicin; Fibrosis; Male; Mice; Mice, Inbred C57BL; Myocardium; Myocytes, Cardiac; Phosphodiesterase 5 Inhibitors; Signal Transduction; Tadalafil; Ventricular Dysfunction, Left

2013
Tadalafil prevents acute heart failure with reduced ejection fraction in mice.
    Cardiovascular drugs and therapy, 2014, Volume: 28, Issue:6

    Topics: Animals; Apoptosis; Carbolines; Cardiomegaly; Cardiomyopathies; Coronary Vessels; Heart Failure; Male; Mice; Mice, Inbred ICR; Myocardial Infarction; Phosphodiesterase Inhibitors; Pulmonary Edema; Tadalafil; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling

2014
The Effect of Sorafenib, Tadalafil and Macitentan Treatments on Thyroxin-Induced Hemodynamic Changes and Cardiac Abnormalities.
    PloS one, 2016, Volume: 11, Issue:4

    Topics: Animals; Blood Pressure; Cardiomyopathies; Disease Models, Animal; Echocardiography; Electrocardiography; Heart Defects, Congenital; Heart Rate; Hemodynamics; Male; Mice; Myocardial Contraction; Niacinamide; Organ Size; Phenylurea Compounds; Pyrimidines; Sorafenib; Sulfonamides; Tadalafil; Thyroxine

2016
Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin-Deficient Hearts.
    Journal of the American Heart Association, 2016, 08-09, Volume: 5, Issue:8

    Topics: Animals; Cardiomyopathies; Cardiotonic Agents; Disease Models, Animal; Dogs; Dystrophin; Echocardiography; Humans; Magnetic Resonance Imaging; Male; Mice; Mice, Inbred mdx; Muscular Dystrophy, Duchenne; Tadalafil; TRPC6 Cation Channel

2016
Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect.
    The Journal of pharmacology and experimental therapeutics, 2010, Sep-01, Volume: 334, Issue:3

    Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Blotting, Western; Carbolines; Cardiomyopathies; Cell Line, Tumor; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Doxorubicin; GATA4 Transcription Factor; Genes, bcl-2; Hemodynamics; Lipid Peroxidation; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Myocytes, Cardiac; Neoplasm Transplantation; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Superoxide Dismutase; Tadalafil; Ultrasonography; Ventricular Function, Left

2010
Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase.
    British journal of pharmacology, 2007, Volume: 150, Issue:5

    Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Antihypertensive Agents; Carbolines; Cardiomyopathies; Cardiovascular Agents; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Doxorubicin; Endothelium, Vascular; Enzyme Inhibitors; Erectile Dysfunction; Heart Failure; Humans; Hypertension; Hypertension, Pulmonary; Imidazoles; Male; Myocardial Infarction; Myocardial Reperfusion Injury; NG-Nitroarginine Methyl Ester; Nitric Oxide; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents; Ventricular Remodeling

2007